Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

Loeb Represents Mountain Crest Acquisition Corp. II in Better Therapeutics Merger

Loeb & Loeb LLP advised Mountain Crest Acquisition Corp. II., a special purpose acquisition company, in connection in its merger with Better Therapeutics, a prescription digital therapeutics company. The company will be known as “Better Therapeutics” and will list on the NASDAQ under symbol “BTTX.” It is currently valued at $187 million.

The Loeb & Loeb deal team representing Mountain Crest in this transaction include partners Tahra Wright, Ronelle C. Porter, Andrei Sirabionian, Jim CzabanMarina Casani, and William J. Voller III.